Relacorilant for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to assess the effect and effectiveness of Relacorilant on improving the glucose levels in the blood, thus potentially improving glucose control in patients with hard to control diabetes.
This study involves the use of an investigational drug called Relacorilant. "Investigational" means that the drug has not yet been approved by the U.S. Food \& Drug Administration (FDA) for treating "mild hypercortisolism" in patients with diabetes. Cortisol is a "stress hormone". The excess production of cortisol can rise blood sugar (glucose) levels and worsen diabetes. Those disturbances might be corrected by the study medication Relacorilant to improve the state of your diabetes.
This study will evaluate the effects of Relacorilant on glucose control and its safety profile. Although the safety of this drug has been tested in prior human research studies, some side effects may not yet be known.
Who Is on the Research Team?
Ralph DeFronzo, MD
Principal Investigator
The University of Texas Health Science Center at San Antonio
Are You a Good Fit for This Trial?
This trial is for people with type 2 diabetes that is hard to control, who also have high cortisol levels (a stress hormone). Participants should not have other serious health issues that would make it unsafe to join.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Relacorilant
Trial Overview
The study tests Relacorilant, an investigational drug, to see if it can help lower blood sugar in people with poorly controlled type 2 diabetes and excess cortisol. The main goal is to check how well the drug works and how safe it is.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive study intervention once daily after screening and dexamethasone suppression test.
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center at San Antonio
Lead Sponsor
Corcept Therapeutics
Industry Sponsor
Dr. Joseph K. Belanoff
Corcept Therapeutics
Chief Executive Officer since 2014
MD from Stanford University
Dr. William Guyer
Corcept Therapeutics
Chief Medical Officer since 2021
PharmD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.